Navigation Links
Amylin to Present Data Showing Investigational Metreleptin Treatment Led to Long-Term Improvements in Diabetes and Lipid Control in Patients with Lipodystrophy
Date:4/15/2011

SAN DIEGO, April 15, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced results from a new analysis of an ongoing, long-term research study of the investigational drug metreleptin, an analog of the human hormone leptin, for the treatment of lipodystrophy. The study is being conducted by investigators from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the National Institutes of Health (NIH). Results from the analysis will be presented by Christian Weyer, M.D., senior vice president, research and development, Amylin Pharmaceuticals, at a late-breaking oral session on Sunday, April 17 at 7:55 a.m. PT at the 20th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists (AACE) in San Diego.

In the study, which has been ongoing for more than 10 years, researchers at the NIH are examining the effect of metreleptin on several metabolic abnormalities, including diabetes and hypertriglyceridemia (high levels of triglycerides in the bloodstream), in patients with rare inherited or acquired forms of lipodystrophy. Treatment with metreleptin resulted in robust reductions from baseline in both A1C and triglycerides. (A1C is a measure of average blood sugar over three months; triglycerides are the major form of fat stored in the body.) These improvements were apparent at four months and generally sustained for up to several years of treatment.

"Patients with rare forms of lipodystrophy are often affected by the disease early in life, are at high risk of acute and chronic complications and, currently, have very limited therapeutic options," said Dr. Weyer. "The results of our analysis reaffirm the potential of metreleptin as an important advance for people living with this chronic and often debilitating metabolic disease. We continue to work diligently toward bringing this potential
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
7. Amylin Pharmaceuticals to Present at the 18th Annual Credit Suisse Healthcare Conference
8. Amylin Pharmaceuticals to Webcast Year-End Financial Results
9. Amylin Highlights 2010 Corporate Priorities at J.P. Morgan Healthcare Conference
10. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
11. Amylin Pharmaceuticals to Present at The Barclays Capital 2010 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... -- Indianapolis interventional medical device maker NICO Corporation ... visualization leader Synaptive Medical announced today ... that they have joined forces to integrate their ... the first of its kind and will make ... BrainPath® interventional access technology and Synaptive,s BrightMatter™ real-time ...
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
(Date:10/20/2014)... , Oct. 20, 2014   Taiho Oncology, ... Ltd. ( Japan ), announced that ... Fast Track designation for TAS-102 (nonproprietary names: trifluridine ... under investigation for the treatment of refractory metastatic ... initiated a rolling NDA submission to the FDA. ...
Breaking Medicine Technology:Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 2Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 3Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 4Indianapolis' NICO Corporation and Toronto's Synaptive Medical, Inc. Announce First-Ever Intervention-Visualization Partnership with Goal to Improve Standard of Care in Neurosurgery 5Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... March 19, 2012  Reportlinker.com ... market research report is ... ... – Gram-negative combination antibiotics ...
... 19, 2012 Reportlinker.com announces that a ... its catalogue: Pharmaceuticals: ... http://www.reportlinker.com/p0191852/Pharmaceuticals-Global-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceu Pharmaceuticals: Global ... top-level data and analysis covering the Pharmaceuticals ...
Cached Medicine Technology:Product Profiles: Pipeline Antibacterials - Gram-Negative Combination Antibiotics Show Promise in MRSA-Focused Pipeline 2Product Profiles: Pipeline Antibacterials - Gram-Negative Combination Antibiotics Show Promise in MRSA-Focused Pipeline 3Product Profiles: Pipeline Antibacterials - Gram-Negative Combination Antibiotics Show Promise in MRSA-Focused Pipeline 4Product Profiles: Pipeline Antibacterials - Gram-Negative Combination Antibiotics Show Promise in MRSA-Focused Pipeline 5Product Profiles: Pipeline Antibacterials - Gram-Negative Combination Antibiotics Show Promise in MRSA-Focused Pipeline 6Product Profiles: Pipeline Antibacterials - Gram-Negative Combination Antibiotics Show Promise in MRSA-Focused Pipeline 7Pharmaceuticals: Global Industry Guide 2Pharmaceuticals: Global Industry Guide 3Pharmaceuticals: Global Industry Guide 4Pharmaceuticals: Global Industry Guide 5Pharmaceuticals: Global Industry Guide 6Pharmaceuticals: Global Industry Guide 7Pharmaceuticals: Global Industry Guide 8Pharmaceuticals: Global Industry Guide 9Pharmaceuticals: Global Industry Guide 10Pharmaceuticals: Global Industry Guide 11Pharmaceuticals: Global Industry Guide 12Pharmaceuticals: Global Industry Guide 13Pharmaceuticals: Global Industry Guide 14Pharmaceuticals: Global Industry Guide 15
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 JZ Fitness, ... nutritional coaching, corporate wellness programming, authorship, international lecturing and ... excited to announce the release of the JZ Fitness ... many years of coaching thousands of individuals on nutrition, ... app that does not require calorie counting or cumbersome ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Rockynol ... Living Center on Oct. 14. The $11 million project ... services, and a cooked-to-order kitchen with full-service restaurant style ... premier choice for first class Assisted Living apartments,” said ... residents deserve the highest quality of care and this ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury ... the greater Phoenix area and across Arizona reports record ... catastrophic automobile accidents. Statistics have indicated a steady increase ... As such, Hastings and Hastings has seen a steady ... who have been injured through no fault of their ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:JZ Fitness Nutrition App Launches on iTunes 2Health News:JZ Fitness Nutrition App Launches on iTunes 3Health News:Rockynol Retirement Community Expands Assisted Living Center 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3
... EVVV ) today,announced that Robert Palmisano, president and ... Sachs Twenty-Ninth Annual Global,Healthcare Conference on Tuesday, June 10, ... p.m. CT). The Goldman Sachs Twenty-Ninth Annual Global,Healthcare Conference ... Point, California., To access the webcast, go to ...
... records now available worldwide, WASHINGTON, May ... Gen.,Eric B. Schoomaker today announced continued expansion ... electronic health record,led by the Army. Medical ... digital recording capabilities and access to battlefield ...
... MISSION VIEJO, Calif., May 27 The Ensign,Group, ... of the Ensign(TM) group of,skilled nursing, rehabilitative care ... has completed the purchase of an 83-bed,skilled nursing ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ), Previously leased ...
... dementia who receive short-term courses of antipsychotic medications are ... who do not take the drugs, according to a ... Internal Medicine, one of the JAMA/Archives journals. , Newer ... on the market for more than a decade and ...
... load on joint, study finds , , MONDAY, May 26 (HealthDay ... of knee osteoarthritis (OA) progression, according to a study by ... The study included 16 men and 24 women, mean age ... leading cause of disability in elderly people. All the participants ...
... tool for mopping up the clumps of mutant protein ... engineered a virus to make an intracellular antibody or ... the brain cells of people with Huntington,s. , Injecting ... mutant huntingtin improves their ability to move their limbs, ...
Cached Medicine News:Health News:Life-Saving Technology Expands Globally to Military Branches - Transforming the Way Medical Care is Documented on the Battlefield 2Health News:The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility 2Health News:The Ensign Group, Inc. Acquires Utah Skilled Nursing Facility 3Health News:Short-term use of antipsychotics in older adults with dementia linked to serious adverse events 2Health News:Cane Use May Cut Progression of Knee Osteoarthritis 2Health News:'Intrabody' can mop up mutant protein in Huntington's disease model 2
Posterior Capsule Polisher, 21 g. Roughened tip, top port. Overall length 23 mm. 5/box....
Irrigating Capsulorhexis Cystotome. Formed angled tip, 27 g. Overall length 16 mm. 5/box....
Irrigating Cystotome, formed, 27 g., short 8 mm curved tip. Overall length 14 mm. 5/box....
Peribulbar Needle, 25 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Medicine Products: